AstraZeneca
-
Company says TGA regulations prevented it from responding to incorrect claims about its vaccine in 2021
-
Britain’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatments
-
Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier
-
Emma Walmsley’s deal, with a high share bonus payout, makes her one of top-paid CEOs in FTSE 100
-
Corporate governance thinktank questions whether Pascal Soriot’s remuneration – 1,000 times the minimum wage – is justifiable
-
Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill
-
Other lives: Specialist in cell biology who helped with the development of a Covid-19 vaccine and treatments for cystic fibrosis
-
UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill
-
CEOs received average increase of 16% while pay of many working for them failed to keep up with inflation
-
The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution
-
Drugmaker’s $4oom offsetting scheme aims to combat climate change and biodiversity loss caused by deforestation
-
UK’s largest stock-market-listed firm weighs up Hong Kong or Shanghai listing to shield it from geopolitical tensions
-
Pascal Soriot says decline in startups across Europe differs markedly from ‘explosion’ of firms and clinical trials in China
-
Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results